Results 1 to 10 of about 5,103,561 (270)

Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231.
Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco   +27 more
doaj   +1 more source

Quick assessment for systematic test statistic inflation/deflation due to null model misspecifications in genome-wide environment interaction studies.

PLoS ONE, 2019
Gene-environment (GxE) interaction is one potential explanation for the missing heritability problem. A popular approach to genome-wide environment interaction studies (GWEIS) is based on regression models involving interactions between genetic variants ...
Masao Ueki, Masahiro Fujii, Gen Tamiya, for Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer’s Disease Metabolomics Consortium   +3 more
doaj   +1 more source

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress.
Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group   +15 more
doaj   +1 more source

Verbal and Nonverbal Memory in Primary Progressive Aphasia: The Three Words-Three Shapes Test

Behavioural Neurology, 2013
Objectives: To investigate cognitive components and mechanisms of learning and memory in primary progressive aphasia (PPA) using a simple clinical measure, the Three Words Three Shapes Test (3W3S).
Sandra Weintraub, Emily Rogalski, Emily Shaw, Sabrina Sawlani, Alfred Rademaker, Christina Wieneke, M.-Marsel Mesulam   +6 more
doaj   +1 more source

White matter signal abnormalities in former National Football League players

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2018
Introduction Later‐life brain alterations in former tackle football players are poorly understood, particularly regarding their relationship with repetitive head impacts (RHIs) and clinical function.
Michael L. Alosco, Inga K. Koerte, Yorghos Tripodis, Megan Mariani, Alicia S. Chua, Johnny Jarnagin, Yashar Rahimpour, Christian Puzo, Rose C. Healy, Brett Martin, Christine E. Chaisson, Robert C. Cantu, Rhoda Au, Michael McClean, Ann C. McKee, Alexander P. Lin, Martha E. Shenton, Ronald J. Killiany, Robert A. Stern   +18 more
doaj   +1 more source

Association between BrainAGE and Alzheimer's disease biomarkers

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION The brain age gap estimation (BrainAGE) method uses a machine learning model to generate an age estimate from structural magnetic resonance imaging (MRI) scans. The goal was to study the association of brain age with Alzheimer's disease (AD)
Yousaf Abughofah, Rachael Deardorff, Aaron Vosmeier, Savannah Hottle, Jeffrey L. Dage, Desarae Dempsey, Liana G. Apostolova, Jared Brosch, David Clark, Martin Farlow, Tatiana Foroud, Sujuan Gao, Sophia Wang, Henrik Zetterberg, Kaj Blennow, Andrew J. Saykin, Shannon L. Risacher   +16 more
doaj   +1 more source

Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles.

PLoS ONE, 2019
Alzheimer's disease (AD) affects millions of people and is a major rising problem in health care worldwide. Recent research suggests that AD could have different subtypes, presenting differences in how the disease develops.
Gerard Martí-Juan, Gerard Sanroma, Gemma Piella, Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer’s Disease Metabolomics Consortium   +3 more
doaj   +1 more source

Alzheimer's disease

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2013
Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia and is responsible for significant individual morbidity and mortality, and economic impact on the health care system. Neurodegeneration (including neuronal atrophy and/or loss) are attributed to extraneuronal toxic amyloid oligomers and proteins, intraneuronal ...
Carly, Oboudiyat, Hilary, Glazer, Alon, Seifan, Christine, Greer, Richard S, Isaacson   +4 more
openaire   +5 more sources

Biomarkers for Alzheimer's disease to differentiate normal, SCD, and MCI subjects and their correlation with cognitive function

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION We assessed plasma biomarkers for the diagnosis of early Alzheimer's disease (AD). METHODS: Subjects were divided into three groups: cognitively unimpaired (CU) (without subjective cognitive decline [SCD]) (n = 113), CU with SCD (n = 152 ...
Allal Boutajangout, Ricardo S. Osorio, Arjun V. Masurkar, Ludovic Debure, Mobeena Ghuman, Wajiha Ahmed, Elizabeth Pirraglia, Alok Vedvyas, Jon Links, Brianna Vega, Karyn Marsh, Joshua Chodosh, Yongzhao Shao, Thomas Wisniewski   +13 more
doaj   +1 more source

Cognitive decline across five cognitive batteries: Sample size implications for clinical trials

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION We evaluated the statistical power for a theoretical randomized trial of anti‐amyloid treatment in preclinical Alzheimer's Disease across five cognitive composites in preclinical Alzheimer's Disease across five cognitive composites ...
Andrea R. Zammit, Ana W. Capuano, Lisa L. Barnes, Julie A. Schneider, Reisa A. Sperling, David A. Bennett, Francine Grodstein   +6 more
doaj   +1 more source